Amgen has invested nearly $2 billion in the U.S. over the last year, building on more than $40 billion invested in U.S. manufacturing and R&D since 2018. The TCJA, reinforced by the One Big Beautiful Bill Act, supports continued investment in domestic science and manufacturing.

Clinical trials are key to turning scientific discovery into new medicines for patients. We appreciate @HHSGov for convening a Clinical Trials Roundtable and discussing ways to reduce research barriers, expand access to research opportunities, and help bring innovation to patients faster.

What’s next for #biosimilars? At Amgen, continued development and manufacturing expertise is helping drive what’s ahead. Watch to learn more: amgen.ly/4eg6DdX

NC’s life sciences ecosystem is driving innovation, growth & opportunity. With more than $1.5 billion invested in the state, Amgen is proud to be part of that momentum. In @BusinessNC, Amgen's Paul Lewus shares how the Research Triangle can maintain its leadership in life sciences: amgen.ly/4vmEkRm

Ohio’s thriving manufacturing hub shows what’s possible when innovation, talent, and pro-growth tax policies align. We're proud to be part of this momentum, investing more than $1.4B in Ohio to help strengthen U.S. leadership in biotech. amgen.ly/3S2ARZd

NEWS: At #ADASciSessions 2026, we’re advancing the conversation around cardiometabolic care. New data reinforce the need for more integrated approaches to prevention, risk reduction, and long-term management across obesity, diabetes and cardiovascular disease. 🔗 Read more: amgen.ly/4uVXTQd $AMGN

People living with cardiometabolic conditions often face interconnected risks that can compound over time. This week at @AmDiabetesAssn’s #ADASciSessions, we’re helping advance the conversation around a more integrated approach to obesity, diabetes and cardiovascular disease and long-term management.

How will AI shape the future of Amgen? CEO Bob Bradway recently joined Sarah Elk and AI pioneer @AndrewYNg on @BainandCompany's Winning with AI podcast to discuss how AI is helping accelerate innovation across drug discovery, development, and manufacturing. 🎙️Watch the full podcast: amgen.ly/4vym86Z $AMGN

📢 Amgen announced the presentation of new data across rare autoimmune & inflammatory diseases at #EULAR2026. Research highlights IgG4-related disease & real-world evidence in ANCA-associated vasculitis. 🔗 Learn more: amgen.ly/4a8lyEu $AMGN

🔬 Small cell lung cancer news: Amgen’s DLL3-targeting therapy is now approved in the European Union for certain patients with extensive-stage small cell lung cancer (#SCLC). 🔗 Learn more: amgen.ly/4feYaZr

Cancer research doesn't stand still at Amgen. At #ASCO2026, we’re sharing new data in SCLC, colorectal cancer, prostate cancer, Ewing sarcoma & more. ➡️ Explore full abstracts: amgen.ly/43nAc7j

Amgen announced the planned retirement of EVP and CFO Peter Griffith. Thomas Dittrich will return to Amgen and succeed Griffith as CFO effective Sept. 1, 2026. “We are grateful to Peter for his leadership and lasting impact on the company,” said Chairman and CEO Robert A. Bradway. More: amgen.ly/4tOOxEm $AMGN

A major milestone in our more than $1.5 billion investment in Holly Springs, North Carolina. The final steel topping beam is now in place at Amgen’s newest advanced manufacturing facility — expanding U.S. biomanufacturing capabilities for the future. $AMGN

Headed to #ECO2026? Join us for our symposium and learn more about the evolving obesity treatment landscape. 🔗Learn more about our scientific approach to obesity: amgen.ly/4np5bZM

How do you navigate B-cell ALL at 21? After years of hospital stays & uncertainty, William is in remission. Now he’s helping other young people advocate for themselves. Read his story: amgen.ly/49pJfI3 @TheMightySite #AmgenSponsored

AMGEN continúa fortaleciendo su presencia en nuestra isla con una inversión adicional de $300 millones, impulsando la creación de empleos, el desarrollo económico y nuevas oportunidades para nuestra gente. Por más de tres décadas, esta alianza ha sido parte clave del crecimiento industrial y científico de Puerto Rico, demostrando la confianza de empresas globales en el talento puertorriqueño y en el potencial de nuestra isla.

Amgen is investing an additional $300M in its U.S. manufacturing network to advance production capacity, enhance next-generation technologies and support a reliable supply of medicines. Total U.S. manufacturing investments announced over the past year now reach nearly $2B. 🔗See how Amgen is leading what’s next in biotech innovation: amgen.ly/4tPfB7l $AMGN

Amgen reports Q1 2026 earnings: amgen.ly/4tcBhcv Safe Harbor: amgen.ly/4cYdXJc $AMGN

Amgen will report Q1 2026 financial results tomorrow. Details here: amgen.ly/4vQMMsC $AMGN

Amgen will report Q1 2026 financial results on Thursday, April 30. Details here: amgen.ly/4ee1JPb $AMGN